Cerebral Semaphorin3D is a novel risk factor for age-associated cognitive impairment

Chien-Yuan Chen1, Yung-Mei Chao2, Ching-Chang Cho3,4

  • 1Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.

Abstract

Insights

MicroRNA-195 (miR-195) protects the brain, but its levels decrease with age. Targeting Sema3D, a protein that increases with age and in dementia patients, may offer a new therapeutic strategy for age-associated cognitive decline.

Area of Science:

  • Neuroscience
  • Genetics
  • Aging Research

Background:

  • MicroRNA-195 (miR-195) has neuroprotective properties and its levels decline with age.
  • This decline suggests a role for miR-195 and its targets in age-associated dementia.

Discussion:

  • Sema3D is identified as a direct target of miR-195 and its levels increase with age and in dementia.
  • Elevated Sema3D impairs cognitive function, reduces dendritic spine density, and affects neural stem cells.
  • Inhibition of Sema3D shows therapeutic potential for age-associated neurodegeneration.

Key Insights:

  • miR-195 knockout mice exhibit cognitive impairment and reduced dendritic spine density.
  • Sema3D overexpression in mice and Drosophila leads to memory deficits and reduced lifespan.
  • Sema3D levels are significantly elevated in dementia patients compared to controls.

Outlook:

  • Sema3D is a potential therapeutic target for dementia.
  • Developing Sema3D inhibitors could offer a novel treatment strategy for age-associated cognitive decline.
  • Further research into Sema3D's mechanisms, including its impact on autophagy and neural stem cells, is warranted.